MET and ALK as Targets for the Treatment of NSCLC

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|24|3914-3932

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3914-3932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Molecular Targets in the Treatment of NSCLC

By  

Current Pharmaceutical Design, Vol. 19, Iss. 30, 2013-09 ,pp. : 5333-5343

Bentham Science Publishers

Access to resources Recommend Favorite

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

By  

Current Clinical Pharmacology, Vol. 11, Iss. 2, 2016-08 ,pp. : 77-87

Bentham Science Publishers

Access to resources Recommend Favorite

Gefitinib sparks INTEREST as NSCLC treatment

By  

Inpharma, Vol. 1, Iss. 1611, 2007-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Erlotinib seals the deal in NSCLC treatment

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Cell cycle inhibitors for the treatment of NSCLC

By Shcherba Marina   Liang Yuanxin   Fernandes David   Perez-Soler Roman   Cheng Haiying  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 991-1004

Informa Healthcare

Access to resources Recommend Favorite